KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Sarepta Therapeutics (SRPT) Invested Capital (2016 - 2025)

Sarepta Therapeutics (SRPT) has 15 years of Invested Capital data on record, last reported at $1.4 billion in Q3 2025.

  • For Q3 2025, Invested Capital fell 44.62% year-over-year to $1.4 billion; the TTM value through Sep 2025 reached $1.4 billion, down 44.62%, while the annual FY2024 figure was $2.7 billion, 27.06% up from the prior year.
  • Invested Capital reached $1.4 billion in Q3 2025 per SRPT's latest filing, roughly flat from $1.4 billion in the prior quarter.
  • Across five years, Invested Capital topped out at $2.7 billion in Q4 2024 and bottomed at $1.0 billion in Q3 2021.
  • Average Invested Capital over 5 years is $1.7 billion, with a median of $1.9 billion recorded in 2022.
  • Peak YoY movement for Invested Capital: surged 91.12% in 2022, then tumbled 48.07% in 2025.
  • A 5-year view of Invested Capital shows it stood at $1.5 billion in 2021, then increased by 29.33% to $1.9 billion in 2022, then increased by 8.71% to $2.1 billion in 2023, then rose by 27.06% to $2.7 billion in 2024, then plummeted by 49.11% to $1.4 billion in 2025.
  • Per Business Quant database, its latest 3 readings for Invested Capital were $1.4 billion in Q3 2025, $1.4 billion in Q2 2025, and $1.1 billion in Q1 2025.